Untitled

Eric Lefkofsky: Entrepreneur and Venture Capitalist

Eric LefKofsky is given to making the world a better place through philanthropic interests and entrepreneurial endeavors. Currently, his interests are centered around coordinating data sets to aid in the treatment of cancers. He and his wife are members of Pledge Giving, and also created the Lefkofsky Family Foundation. It is estimated about one-half of their annual wealth is marked toward philanthropic causes.

Lefkofsky’s family foundation has some of the following initiatives as its focus: the arts, medicine, education and basic human rights. Lefkofsky is on several boards of human interest in the Chicago area. His net worth is estimated to be $2 billion USD.

Eric Lefkofsky is co-founder, of numerous venture capital marketplace firms. These include Lightbank, Media Ocean, Groupon where he is also chairman and Tempus, which is his current interest and where he serves as CEO. Moreover, Lefkofsky is a graduate of the University of Michigan. A recent article at  details  Tempus acquiring access to a sizeable clinical oncology patient database called CancerlinQ. It contains treatment results from over 500,000 patient records. In a partnership extending for 10 years with CancerlinQ and another company, Precision Health AI, Tempus teams will look for patterns to reveal those treatment protocols that are more effective in addressing cancers. Lefkofsky voices optimism and anticipates this collaboration to touch an estimated 30 percent of cancer patients in the coming year.

Tempus has partnerships with about fifty hospitals and clinics across the US. These include the Mayo Clinic, Cleveland Clinic, Duke University Medical School, and the Knight Cancer Institute at Ohio State University. The challenge according to the Tempus Board of Governors Chairman is to compile the medical records into a structured format. Most facilities previously utilized data collection methods unique to their operation. The goal is to have previous patient data influence the treatment outcome received by patients currently undergoing protocols.

Leave a Reply

Your email address will not be published. Required fields are marked *